Rogosin Institute Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Rogosin Institute's estimated annual revenue is currently $127.2M per year.(i)
  • Rogosin Institute's estimated revenue per employee is $337,500

Employee Data

  • Rogosin Institute has 377 Employees.(i)
  • Rogosin Institute grew their employee count by 6% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$6.9M323%N/AN/A
#2
$13.4M5510%N/AN/A
#3
$25.4M9411%N/AN/A
#4
$78.4M26416%N/AN/A
#5
$9.3M4310%N/AN/A
#6
$51.1M17224%N/AN/A
#7
$65M2190%N/AN/A
#8
$44.8M1519%N/AN/A
#9
$6.7M31-11%N/AN/A
#10
$9.5M447%N/AN/A
Add Company

What Is Rogosin Institute?

The Rogosin Institute is the premier not-for-profit medical treatment and research institution for kidney disease, including dialysis and transplantation. We offer patients a wide range of services focused on the diagnosis, treatment, and management of chronic and end-stage kidney disease.\n\nRogosin is affiliated with NewYork-Presbyterian Hospital, Weill Cornell Medical College and is a proud member of the NewYork-Presbyterian Regional Hospital Network. \n\nLike us on Facebook - www.facebook.com/rogosin\nFollow us on Twitter - www.twitter.com/rogosin \nFollow us on Instagram - www.instagram.com/rogosininstitute

keywords:N/A

N/A

Total Funding

377

Number of Employees

$127.2M

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Rogosin Institute News

2022-04-06 - New Research Affirms Increase in Access, Equity of COVID-19 ...

... to receive at least one dose of COVID-19 vaccine in a dialysis center. ... and the American Society of Nephrology and Rogosin Institute.

2022-03-22 - Comedian Lewis Black will hit the stage this November in Beaumont

... Lincoln Center, Brooks Atkinson Theatre, New York City Center, the Main Stage at ... The Rogosin Institute, and The 52nd Street Project.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$143.7M3775%N/A
#2
$114.5M37717%N/A
#3
$68.5M378-2%N/A
#4
$85.1M3789%N/A
#5
$137M3784%N/A